Experiments with erlotinib (Tarceva) and the human EGFR-neutralizing mAb225 (non-humanized C225, cetuximab/Erbitux) suggest ligand-dependent EGFR signaling on cancer cells is required. The gene discussed is EGFR; the disease is cancer.